CD79B and diffuse large B-cell lymphoma: Mutations in any part of this pathway can potentially be problematic and lead to overactivation, such as loss of negative feedback ITAM mutation of CD79B which is detected in near 20% of ABC DLBCL cases (Davis et al., 2010).